Sansure Biotech Inc. (SHA:688289)

Market Cap	10.50B -15.1%
Revenue (ttm)	1.65B +13.0%
Net Income	198.15M -28.1%
EPS	0.34 -27.7%
Shares Out	574.18M
PE Ratio	53.76
Forward PE	26.59
Dividend	0.54 (3.01%)
Ex-Dividend Date	n/a

Volume	3,048,569
Average Volume	4,783,508
Open	17.66
Previous Close	17.87
Day's Range	17.58 - 18.30
52-Week Range	17.73 - 23.45
Beta	0.71
RSI	35.78
Earnings Date	Apr 30, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,409
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2025, Sansure Biotech's revenue was 1.65 billion, an increase of 13.04% compared to the previous year's 1.46 billion. Earnings were 198.15 million, a decrease of -28.10%.